Adherex Technologies (NASDAQ:FENC – Get Free Report) and Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.
Analyst Ratings
This is a summary of recent recommendations and price targets for Adherex Technologies and Jaguar Animal Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adherex Technologies | 1 | 1 | 4 | 0 | 2.50 |
| Jaguar Animal Health | 1 | 0 | 0 | 0 | 1.00 |
Adherex Technologies presently has a consensus target price of $17.00, suggesting a potential upside of 63.78%. Given Adherex Technologies’ stronger consensus rating and higher probable upside, equities analysts clearly believe Adherex Technologies is more favorable than Jaguar Animal Health.
Valuation & Earnings
This table compares Adherex Technologies and Jaguar Animal Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adherex Technologies | $44.64 million | 8.17 | -$9.74 million | ($0.13) | -79.85 |
| Jaguar Animal Health | $11.51 million | 0.07 | -$53.43 million | ($3,731.33) | -0.00 |
Adherex Technologies has higher revenue and earnings than Jaguar Animal Health. Adherex Technologies is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by insiders. Comparatively, 0.1% of Jaguar Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Adherex Technologies has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500.
Profitability
This table compares Adherex Technologies and Jaguar Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adherex Technologies | -6.09% | -5.71% | -2.37% |
| Jaguar Animal Health | -187.88% | N/A | -131.45% |
Summary
Adherex Technologies beats Jaguar Animal Health on 12 of the 13 factors compared between the two stocks.
About Adherex Technologies
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
